Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-trace').style.display = (document.getElementById('cakeErr67f1407c87cbe-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f1407c87cbe-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-code').style.display = (document.getElementById('cakeErr67f1407c87cbe-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-context').style.display = (document.getElementById('cakeErr67f1407c87cbe-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f1407c87cbe-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f1407c87cbe-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24030,
		&#039;title&#039; =&gt; &#039;India patent regime not about access to medicine: U.S body&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-patent-regime-not-about-access-to-medicine-u-s-body-24203&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24203,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24030,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicines,generic drugs,medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24030,
	&#039;title&#039; =&gt; &#039;India patent regime not about access to medicine: U.S body&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-patent-regime-not-about-access-to-medicine-u-s-body-24203&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24203,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24030
$metaTitle = &#039;LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body&#039;
$metaKeywords = &#039;generic medicines,generic drugs,medicines,patents,Health&#039;
$metaDesc = &#039;
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body | Im4change.org</title>
    <meta name="description" content="
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India patent regime not about access to medicine: U.S body</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br /><em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;</p><p align="justify">In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;</p><p align="justify">The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.</p><p align="justify">In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.</p><p align="justify">&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.</p><p align="justify">Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.</p><p align="justify">In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.</p><p align="justify">It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.</p><p align="justify">&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-trace').style.display = (document.getElementById('cakeErr67f1407c87cbe-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f1407c87cbe-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-code').style.display = (document.getElementById('cakeErr67f1407c87cbe-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-context').style.display = (document.getElementById('cakeErr67f1407c87cbe-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f1407c87cbe-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f1407c87cbe-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24030,
		&#039;title&#039; =&gt; &#039;India patent regime not about access to medicine: U.S body&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-patent-regime-not-about-access-to-medicine-u-s-body-24203&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24203,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24030,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicines,generic drugs,medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24030,
	&#039;title&#039; =&gt; &#039;India patent regime not about access to medicine: U.S body&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-patent-regime-not-about-access-to-medicine-u-s-body-24203&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24203,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24030
$metaTitle = &#039;LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body&#039;
$metaKeywords = &#039;generic medicines,generic drugs,medicines,patents,Health&#039;
$metaDesc = &#039;
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body | Im4change.org</title>
    <meta name="description" content="
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India patent regime not about access to medicine: U.S body</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br /><em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;</p><p align="justify">In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;</p><p align="justify">The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.</p><p align="justify">In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.</p><p align="justify">&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.</p><p align="justify">Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.</p><p align="justify">In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.</p><p align="justify">It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.</p><p align="justify">&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-trace').style.display = (document.getElementById('cakeErr67f1407c87cbe-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f1407c87cbe-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-code').style.display = (document.getElementById('cakeErr67f1407c87cbe-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1407c87cbe-context').style.display = (document.getElementById('cakeErr67f1407c87cbe-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f1407c87cbe-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f1407c87cbe-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24030,
		&#039;title&#039; =&gt; &#039;India patent regime not about access to medicine: U.S body&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-patent-regime-not-about-access-to-medicine-u-s-body-24203&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24203,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24030,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicines,generic drugs,medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24030,
	&#039;title&#039; =&gt; &#039;India patent regime not about access to medicine: U.S body&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-patent-regime-not-about-access-to-medicine-u-s-body-24203&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24203,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24030
$metaTitle = &#039;LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body&#039;
$metaKeywords = &#039;generic medicines,generic drugs,medicines,patents,Health&#039;
$metaDesc = &#039;
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India&#039;s recent pattern of pharma patent denials, pointing out that the country&#039;s actions &amp;quot;are not about access to medicine.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the case of Swiss drug-maker Novartis, whose cancer drug&#039;s patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &amp;quot;more expensive for Indian patients.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chamber&#039;s argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR&#039;s expected trade enforcement actions could affect.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In an indirect jab at India&#039;s support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&amp;quot; the chamber said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Thus, the chamber points out, it is actually &amp;quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the chamber has also asked that India be classified as a &amp;lsquo;priority foreign country&#039;- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&amp;quot;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-patent-regime-not-about-access-to-medicine-u-s-body-24203.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body | Im4change.org</title>
    <meta name="description" content="
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India patent regime not about access to medicine: U.S body</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br /><em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;</p><p align="justify">In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;</p><p align="justify">The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.</p><p align="justify">In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.</p><p align="justify">&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.</p><p align="justify">Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.</p><p align="justify">In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.</p><p align="justify">It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.</p><p align="justify">&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 24030,
		'title' => 'India patent regime not about access to medicine: U.S body',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
<em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;
</p>
<p align="justify">
In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;
</p>
<p align="justify">
The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.
</p>
<p align="justify">
In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
</p>
<p align="justify">
&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.
</p>
<p align="justify">
Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.
</p>
<p align="justify">
In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
</p>
<p align="justify">
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
</p>
<p align="justify">
&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;
</p>',
		'credit_writer' => 'The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'india-patent-regime-not-about-access-to-medicine-u-s-body-24203',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 24203,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 24030,
	'metaTitle' => 'LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body',
	'metaKeywords' => 'generic medicines,generic drugs,medicines,patents,Health',
	'metaDesc' => '
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the...',
	'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br /><em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;</p><p align="justify">In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;</p><p align="justify">The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.</p><p align="justify">In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.</p><p align="justify">&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.</p><p align="justify">Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.</p><p align="justify">In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.</p><p align="justify">It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.</p><p align="justify">&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 24030,
	'title' => 'India patent regime not about access to medicine: U.S body',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
<em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;
</p>
<p align="justify">
In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;
</p>
<p align="justify">
The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.
</p>
<p align="justify">
In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.
</p>
<p align="justify">
&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.
</p>
<p align="justify">
Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.
</p>
<p align="justify">
In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.
</p>
<p align="justify">
It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.
</p>
<p align="justify">
&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;
</p>',
	'credit_writer' => 'The Hindu, 10 February, 2014, http://www.thehindu.com/business/Industry/india-patent-regime-not-about-access-to-medicine-us-body/article5674425.ece?homepage=true',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'india-patent-regime-not-about-access-to-medicine-u-s-body-24203',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 24203,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 24030
$metaTitle = 'LATEST NEWS UPDATES | India patent regime not about access to medicine: U.S body'
$metaKeywords = 'generic medicines,generic drugs,medicines,patents,Health'
$metaDesc = '
-The Hindu



Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br /><em>Chennai: </em>With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions &quot;are not about access to medicine.&quot;</p><p align="justify">In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming &quot;more expensive for Indian patients.&quot;</p><p align="justify">The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect.</p><p align="justify">In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free.</p><p align="justify">&quot;In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India,&quot; the chamber said.</p><p align="justify">Thus, the chamber points out, it is actually &quot;more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before&quot;.</p><p align="justify">In its submission, the chamber has also asked that India be classified as a &lsquo;priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions.</p><p align="justify">It also warns of a possible domino effect, with other countries following India as an example of bad behaviour.</p><p align="justify">&quot;India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model.&quot;</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

India patent regime not about access to medicine: U.S body

-The Hindu Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions "are not about access to medicine." In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that the patent revocation led to the drug actually becoming "more expensive for Indian patients." The chamber's argument is part of a set of recent recommendations, which were submitted to the office of the U.S trade representative (UTSR). The recommendations are being by trade experts as a pointer to what sectors the USTR's expected trade enforcement actions could affect. In an indirect jab at India's support towards generic drug-makers, the Global Intellectual Property Centre (GIPC) of the chamber of commerce has pointed out that in many cases, multi-national drug-makers would give away the drug for free. "In the case of Glivec, Novartis provided the leukaemia drug to 95 per cent of patient population for free. The annual cost for Glivec generic treatment is approximately three to for times the average annual income in India," the chamber said. Thus, the chamber points out, it is actually "more expensive for Indian patents to obtain access to these medicines after the patent revocation than it was before". In its submission, the chamber has also asked that India be classified as a ‘priority foreign country'- a tag that is generally given to the worst intellectual property offenders, and is also a classification that could trigger trade sanctions. It also warns of a possible domino effect, with other countries following India as an example of bad behaviour. "India's policies are clearly discriminatory, in contravention to their obligations under TRIPS (The Agreement on Trade Related Aspects of Intellectual Property Rights). In addition, other countries such as South Africa, Brazil, Argentina and even China are closely monitoring this new Indian IP model."